"Tubulis GmbH Secures Record €308 Million in Series C Financing, Setting New Benchmark for European Biotech"

"Tubulis GmbH has successfully completed a Series C financing round, raising EUR 308 million, making it the largest Series C funding for a European biotech company and the largest for a privately held developer of antibody-drug conjugates globally. The funds will be used to advance the clinical development of Tubulis's lead candidate, TUB-040, for treating ovarian cancer and lung adenocarcinoma. The financing was led by Venrock Healthcare Capital Partners, with participation from new and existing investors. CMS's Munich venture capital team provided legal advice throughout the financing process."

**Law Firms Involved in the Transaction:** CMS acted as legal counsel for Tubulis GmbH during its Series C financing round. **Transaction Overview:** Tubulis GmbH has successfully completed a Series C financing round, raising EUR 308 million. This financing round is notable for being the largest Series C round for a European biotech company and the largest globally for a privately held developer of antibody-drug conjugates (ADCs). The funds raised will be utilized to advance the clinical development of Tubulis's lead candidate, TUB-040, targeting earlier lines of therapy and additional tumor indications. **Legal Team:** The CMS Munich-based venture capital team, led by Stefan-Ulrich Müller, provided comprehensive legal advice throughout the financing process. The team has been advising Tubulis since 2020 on various legal matters, including venture capital financing, corporate law, intellectual property, licensing, and employment law. Specific details regarding additional lawyers involved in the transaction were not provided in the press release.

"Tubulis GmbH Secures Record €308 Million in Series C Financing, Setting New Benchmark for European Biotech"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads